Vagus nerve stimulation in children with refractory seizures associated with Lennox - Gastaut syndrome

Michael Frost, John Gates, Sandra L. Helmers, James Wheless, Paul Levisohn, Carmelo Tardo, Joan A. Conry

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Summary: Purpose: Vagus nerve stimulation (VNS) is approved for use for refractory partial seizures. Nevertheless, information regarding VNS therapy for special populations, including Lennox - Gastaut syndrome (LGS) is limited. We discuss the effectiveness, tolerability, and safety of VNS therapy in patients with LGS. Methods: A six-center, retrospective study evaluated the effectiveness of VNS therapy in patients with LGS at 3 and 6 months and compared preimplant and postimplant seizure frequency. Adverse effects and quality of life (QOL) were included as secondary measures. Results: Fifty patients, median age 13 years, with medically refractory epilepsy, were implanted. Median age at onset of seizures was 1.4 years, and a median of nine anticonvulsants (AEDs) had been tried before implantation. Data-collection forms were designed for retrospectively gathering data on each patient's preimplant history, seizures, implants, device settings, QOL, and adverse events. Median reductions in total seizures were 42% at 1 month, 58.2% at 3 months, and 57.9% at 6 months. The most common adverse events reported were voice alteration and coughing during stimulation. Other uncommon adverse events included increased drooling and behavioral changes. Investigators noted that QOL had improved for some patients in the study. Conclusions: VNS is an effective treatment for medically refractory epilepsy in LGS. This treatment is well tolerated, safe, and may improve QOL.

Original languageEnglish (US)
Pages (from-to)1148-1152
Number of pages5
JournalEpilepsia
Volume42
Issue number9
DOIs
StatePublished - Oct 20 2001

Fingerprint

Vagus Nerve Stimulation
Seizures
Quality of Life
Epilepsy
Sialorrhea
Therapeutics
Age of Onset
Anticonvulsants
Retrospective Studies
History
Research Personnel
Lennox Gastaut Syndrome
Safety
Equipment and Supplies
Population

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Vagus nerve stimulation in children with refractory seizures associated with Lennox - Gastaut syndrome. / Frost, Michael; Gates, John; Helmers, Sandra L.; Wheless, James; Levisohn, Paul; Tardo, Carmelo; Conry, Joan A.

In: Epilepsia, Vol. 42, No. 9, 20.10.2001, p. 1148-1152.

Research output: Contribution to journalArticle

Frost, Michael ; Gates, John ; Helmers, Sandra L. ; Wheless, James ; Levisohn, Paul ; Tardo, Carmelo ; Conry, Joan A. / Vagus nerve stimulation in children with refractory seizures associated with Lennox - Gastaut syndrome. In: Epilepsia. 2001 ; Vol. 42, No. 9. pp. 1148-1152.
@article{db5d0a82375044aaadc0214e1bc48123,
title = "Vagus nerve stimulation in children with refractory seizures associated with Lennox - Gastaut syndrome",
abstract = "Summary: Purpose: Vagus nerve stimulation (VNS) is approved for use for refractory partial seizures. Nevertheless, information regarding VNS therapy for special populations, including Lennox - Gastaut syndrome (LGS) is limited. We discuss the effectiveness, tolerability, and safety of VNS therapy in patients with LGS. Methods: A six-center, retrospective study evaluated the effectiveness of VNS therapy in patients with LGS at 3 and 6 months and compared preimplant and postimplant seizure frequency. Adverse effects and quality of life (QOL) were included as secondary measures. Results: Fifty patients, median age 13 years, with medically refractory epilepsy, were implanted. Median age at onset of seizures was 1.4 years, and a median of nine anticonvulsants (AEDs) had been tried before implantation. Data-collection forms were designed for retrospectively gathering data on each patient's preimplant history, seizures, implants, device settings, QOL, and adverse events. Median reductions in total seizures were 42{\%} at 1 month, 58.2{\%} at 3 months, and 57.9{\%} at 6 months. The most common adverse events reported were voice alteration and coughing during stimulation. Other uncommon adverse events included increased drooling and behavioral changes. Investigators noted that QOL had improved for some patients in the study. Conclusions: VNS is an effective treatment for medically refractory epilepsy in LGS. This treatment is well tolerated, safe, and may improve QOL.",
author = "Michael Frost and John Gates and Helmers, {Sandra L.} and James Wheless and Paul Levisohn and Carmelo Tardo and Conry, {Joan A.}",
year = "2001",
month = "10",
day = "20",
doi = "10.1046/j.1528-1157.2001.23900.x",
language = "English (US)",
volume = "42",
pages = "1148--1152",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Vagus nerve stimulation in children with refractory seizures associated with Lennox - Gastaut syndrome

AU - Frost, Michael

AU - Gates, John

AU - Helmers, Sandra L.

AU - Wheless, James

AU - Levisohn, Paul

AU - Tardo, Carmelo

AU - Conry, Joan A.

PY - 2001/10/20

Y1 - 2001/10/20

N2 - Summary: Purpose: Vagus nerve stimulation (VNS) is approved for use for refractory partial seizures. Nevertheless, information regarding VNS therapy for special populations, including Lennox - Gastaut syndrome (LGS) is limited. We discuss the effectiveness, tolerability, and safety of VNS therapy in patients with LGS. Methods: A six-center, retrospective study evaluated the effectiveness of VNS therapy in patients with LGS at 3 and 6 months and compared preimplant and postimplant seizure frequency. Adverse effects and quality of life (QOL) were included as secondary measures. Results: Fifty patients, median age 13 years, with medically refractory epilepsy, were implanted. Median age at onset of seizures was 1.4 years, and a median of nine anticonvulsants (AEDs) had been tried before implantation. Data-collection forms were designed for retrospectively gathering data on each patient's preimplant history, seizures, implants, device settings, QOL, and adverse events. Median reductions in total seizures were 42% at 1 month, 58.2% at 3 months, and 57.9% at 6 months. The most common adverse events reported were voice alteration and coughing during stimulation. Other uncommon adverse events included increased drooling and behavioral changes. Investigators noted that QOL had improved for some patients in the study. Conclusions: VNS is an effective treatment for medically refractory epilepsy in LGS. This treatment is well tolerated, safe, and may improve QOL.

AB - Summary: Purpose: Vagus nerve stimulation (VNS) is approved for use for refractory partial seizures. Nevertheless, information regarding VNS therapy for special populations, including Lennox - Gastaut syndrome (LGS) is limited. We discuss the effectiveness, tolerability, and safety of VNS therapy in patients with LGS. Methods: A six-center, retrospective study evaluated the effectiveness of VNS therapy in patients with LGS at 3 and 6 months and compared preimplant and postimplant seizure frequency. Adverse effects and quality of life (QOL) were included as secondary measures. Results: Fifty patients, median age 13 years, with medically refractory epilepsy, were implanted. Median age at onset of seizures was 1.4 years, and a median of nine anticonvulsants (AEDs) had been tried before implantation. Data-collection forms were designed for retrospectively gathering data on each patient's preimplant history, seizures, implants, device settings, QOL, and adverse events. Median reductions in total seizures were 42% at 1 month, 58.2% at 3 months, and 57.9% at 6 months. The most common adverse events reported were voice alteration and coughing during stimulation. Other uncommon adverse events included increased drooling and behavioral changes. Investigators noted that QOL had improved for some patients in the study. Conclusions: VNS is an effective treatment for medically refractory epilepsy in LGS. This treatment is well tolerated, safe, and may improve QOL.

UR - http://www.scopus.com/inward/record.url?scp=0034789323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034789323&partnerID=8YFLogxK

U2 - 10.1046/j.1528-1157.2001.23900.x

DO - 10.1046/j.1528-1157.2001.23900.x

M3 - Article

VL - 42

SP - 1148

EP - 1152

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 9

ER -